WO2022170126A3 - Compounds specific to coronavirus s protein and uses thereof - Google Patents

Compounds specific to coronavirus s protein and uses thereof Download PDF

Info

Publication number
WO2022170126A3
WO2022170126A3 PCT/US2022/015357 US2022015357W WO2022170126A3 WO 2022170126 A3 WO2022170126 A3 WO 2022170126A3 US 2022015357 W US2022015357 W US 2022015357W WO 2022170126 A3 WO2022170126 A3 WO 2022170126A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cov
antibodies
binding fragments
coronaviruses
Prior art date
Application number
PCT/US2022/015357
Other languages
French (fr)
Other versions
WO2022170126A2 (en
Inventor
Laura Walker
C. Garrett RAPPAZZO
Mrunal SAKHARKAR
Laura DEVEAU
Chengzi I. KAKU
Original Assignee
Adagio Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adagio Therapeutics, Inc. filed Critical Adagio Therapeutics, Inc.
Publication of WO2022170126A2 publication Critical patent/WO2022170126A2/en
Publication of WO2022170126A3 publication Critical patent/WO2022170126A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present disclosure is directed to antibodies and antigen binding fragments thereof having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
PCT/US2022/015357 2021-02-05 2022-02-04 Compounds specific to coronavirus s protein and uses thereof WO2022170126A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163146090P 2021-02-05 2021-02-05
US63/146,090 2021-02-05
US202163151278P 2021-02-19 2021-02-19
US63/151,278 2021-02-19
US202163181467P 2021-04-29 2021-04-29
US63/181,467 2021-04-29
US202163187982P 2021-05-13 2021-05-13
US63/187,982 2021-05-13

Publications (2)

Publication Number Publication Date
WO2022170126A2 WO2022170126A2 (en) 2022-08-11
WO2022170126A3 true WO2022170126A3 (en) 2022-09-15

Family

ID=82741823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/015357 WO2022170126A2 (en) 2021-02-05 2022-02-04 Compounds specific to coronavirus s protein and uses thereof

Country Status (2)

Country Link
TW (1) TW202246315A (en)
WO (1) WO2022170126A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114230674B (en) * 2020-12-01 2023-09-26 中国医学科学院基础医学研究所 Novel coronavirus S protein receptor binding domain fusion protein containing Fc domain and application thereof
WO2023154824A1 (en) * 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
WO2024036313A2 (en) * 2022-08-12 2024-02-15 The Rockefeller University Anti-sars-cov-2 antibodies and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009136A1 (en) * 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
WO2009111450A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
WO2016014434A2 (en) * 2014-07-22 2016-01-28 Sutro Biopharma, Inc. Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
WO2018075961A1 (en) * 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US20190351049A1 (en) * 2014-05-23 2019-11-21 Regeneron Pharmaceuticals, Inc. Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
WO2019232503A1 (en) * 2018-06-01 2019-12-05 University Of Southern California Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
US20200024319A1 (en) * 2015-04-10 2020-01-23 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009136A1 (en) * 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
WO2009111450A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
US20190351049A1 (en) * 2014-05-23 2019-11-21 Regeneron Pharmaceuticals, Inc. Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
WO2016014434A2 (en) * 2014-07-22 2016-01-28 Sutro Biopharma, Inc. Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
US20200024319A1 (en) * 2015-04-10 2020-01-23 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
WO2018075961A1 (en) * 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2019232503A1 (en) * 2018-06-01 2019-12-05 University Of Southern California Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROTKB 23 May 2018 (2018-05-23), ANONYMOUS : "A0A2P2PVE6 · A0A2P2PVE6_RHIMU", XP055968825, retrieved from UNIPROT Database accession no. A0A2P2PVE6 *

Also Published As

Publication number Publication date
TW202246315A (en) 2022-12-01
WO2022170126A2 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
WO2022170126A3 (en) Compounds specific to coronavirus s protein and uses thereof
MX2022012685A (en) Compounds specific to coronavirus s protein and uses thereof.
MX2018012470A (en) Humanized anti-pacap antibodies and uses thereof.
EA201991099A1 (en) ANTIBODIES AGAINST CD73 AND THEIR APPLICATION
AU2011336470A8 (en) Anti-NGF compositions and use thereof
EA200970335A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
NZ598063A (en) Gram-positive bacteria specific binding compounds
WO2016168768A3 (en) Anti-pacap antibodies and uses thereof
WO2020057540A8 (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
ATE390928T1 (en) COMPOSITIONS FOR TREATING SKIN DISEASES
NZ624752A (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
MX2021011715A (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof.
WO2022150654A3 (en) Antigen-binding polypeptides specific for coronaviruses and uses thereof
MX2023007611A (en) Anti-il1rap antibody.
WO2021212053A8 (en) Therapeutic musk antibodies
MX2023002901A (en) Antibodies that bind to il1rap and uses thereof.
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
SG148190A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
WO2021067633A3 (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
WO2023193017A3 (en) Sars-cov2 antibodies and uses thereof
WO2024050356A3 (en) Sars-cov2 antibodies and uses thereof
ZA202110285B (en) Antibodies and methods of use
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22750488

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22750488

Country of ref document: EP

Kind code of ref document: A2